Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 14/20 | 0.51 |
| ▸ | CCND1 | P24385 | 6/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 6/20 | 0.51 |
| ▸ | CCND3 | P30281 | 4/20 | 0.49 |
| ▸ | CCND2 | P30279 | 3/20 | 0.49 |
| ▸ | TTK | P33981 | 2/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14681895 | 0.85 | CDK4 (0.55) | CDK4CCND1CDK6CCND3CCND2 | |
| SCHEMBL13616299 | 0.84 | CCND3 (0.46) | CDK4CCND1CDK6CCND3CCND2 | |
| SCHEMBL13616300 | 0.83 | CCND3 (0.49) | CDK4CCND1CDK6CCND3CCND2 | |
| SCHEMBL21158419 | 0.82 | CDK4 (0.54) | CDK4CCND1CDK6CCND3CCND2 | |
| SCHEMBL13616286 | 0.82 | CDK4 (0.54) | CDK4CCND1CDK6CCND3CCND2 | |
| SCHEMBL11984212 | 0.82 | CDK4 (0.57) | CDK4CCND1CDK6CCND3CCND2 | |
| SCHEMBL12639355 | 0.81 | CDK4 (0.58) | CDK4CCND1CDK6CCND3CCND2 | |
| SCHEMBL11984379 | 0.81 | CDK4 (0.57) | CDK4CCND1CDK6CCND3CCND2 | |
| SCHEMBL7712932 | 0.80 | MARK3 (0.53) | CDK4CCND1CDK6CCND3CCND2 | |
| SCHEMBL11976960 | 0.79 | CDK4 (0.55) | CDK4CCND1CDK6CCND3CCND2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | CDK4 4/4885CCND1 615/4885CDK6 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.